Proteomics in Biomedicine and Pharmacology

Erscheinungsjahr 2014
ISBN: 978-0-12-800453-1
Verlag: William Andrew Publishing

Buch, Englisch, 376 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 790 g

Volume 95 of Advances in Protein Chemistry and Structural Biology focuses on advances in proteomic techniques and their application in biomedicine and pharmacology. This volume describes in detail the applications of these techniques in studying a number of diseases and specific protein modifications and profiles, including phosphoproteomics, glycoproteomics, and more.

Published continuously since 1944, the Advances in Protein Chemistry and Structural Biology series is the essential resource for protein chemists. Each volume brings forth new information about protocols and analysis of proteins. Each thematically organized volume is guest edited by leading experts in a broad range of protein-related topics.

Zielgruppe

<p>The intended audiences for this volume are researchers and specialists in biomedicine and pharmacology interested in using cutting edge proteomics strategies for discovery of suitable therapeutic targets and design of biologically active molecules. This volume would be also of a great use to students working on projects from the abovementioned areas.</p>

Autoren/Hrsg.

Weitere Mitwirkende

Donev, Rossen

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Biomedizin, Medizinische Forschung, Klinische Studien
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Naturwissenschaften Biowissenschaften Proteinforschung

Inhaltsverzeichnis

- Application of Cutting-Edge Proteomics Technologies for Elucidating Host-Bacteria Interactions

Bernardo A. Petriz and Octavio Luiz Franco

- Phosphoproteomic Techniques and Applications

Ed Dudley and A. Elizabeth Bond

- Recent Advances in Mass Spectrometry-Based Glycoproteomics

Dustin C. Frost and Lingjun Li

- Proteomics and Proteogenomics Approaches for Oral Diseases

Nicola Luigi Bragazzi, Eugenia Pechkova and Claudio Nicolini

- Advances in Nanocrystallography as a Proteomic Tool

Eugenia Pechkova, Nicola Luigi Bragazzi and Claudio Nicolini

- Modern Mass Spectrometry Based Structural Proteomics

Evgeniy V. Petrotchenko and Christoph H. Borchers

- Organellar Proteomics of Embryonic Stem Cells

Faezeh Shekari, Hossein Baharvand and Ghasem Hosseini Salekdeh

- Screening of Protein-Protein and Protein-DNA Interactions Using Microarrays: Applications in Biomedicine

Juan Casado-Vela, Manuel Fuentes and José Manuel Franco-Zorrilla

- Application of Proteomics in Diagnosis of ADHD, Schizophrenia, Major Depression and Suicidal Behaviour Khaled Alawam

Über Autor(innen)

Donev, Rossen
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.